ecropolis

Progress Toward Poliomyelitis Eradication ― Afghanistan | Moderna Received FDA Emergency Use Authorization For Their Omicron-Targeting Bivalent Covid-19 Booster Vaccine In Children | Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons | Authorized Updated (Bivalent) COVID-19 Vaccines for Children | Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster | Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir | The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions | Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters

SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022 | Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes | Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals
| Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants | Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022 | Triage of patients with Ebola virus disease

Is the risk of still and preterm birth affected by the timing of symptomatic SARS-CoV-2 infection during pregnancy? | Effectiveness of Influenza Vaccination of Pregnant Women for Prevention of Maternal and Early Infant Influenza-Associated Hospitalizations in South Africa | A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes | Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic® induce durable B cell memory responses comparable to replicating smallpox vaccines | Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals